Datroway
Datroway (datopotamab deruxtecan) is a prescription brand-name medication classified as a TROP2-directed antibody-drug conjugate (ADC). It is used to treat adults with HR-positive, HER2-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have previously received endocrine therapy and at least one chemotherapy regimen. The medication works by binding to TROP2 proteins on cancer cells and delivering a cytotoxic agent directly to destroy them.
Datroway is a targeted therapy for certain types of advanced breast cancer that delivers cancer-killing medication directly to tumor cells expressing TROP2 protein.
Key facts at a glance
- RxNorm
- 2703041
- Generic
- Datroway
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Datroway is indicated for the treatment of adults with hormone receptor (HR)-positive, HER2-negative breast cancer that has become metastatic or cannot be surgically removed, and who have received prior endocrine therapy and chemotherapy for metastatic disease.
Datroway is a type of targeted therapy called an antibody-drug conjugate (ADC). It consists of an antibody that specifically recognizes and binds to the TROP2 protein found on certain cancer cells. Once bound, the medication delivers a cytotoxic (cell-killing) agent directly into the cancer cell, leading to cell death.
Datroway is administered intravenously by a healthcare professional. Common side effects may include eye problems, nausea, fatigue, and liver issues. Patients should discuss all potential risks and benefits with their healthcare provider. Regular monitoring and eye exams may be required during treatment. This medication should only be used under the supervision of a qualified oncologist.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy